Skip to Content

Antibody Cocktail Enhances Clearance of SARS-CoV-2 Virus

MONDAY, Dec. 21, 2020 -- An interim analysis of data from an ongoing phase 1 to 3 trial shows that an antibody cocktail enhances clearance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, according to a study published online Dec. 17 in the New England Journal of Medicine.

David M. Weinreich, M.D., from Regeneron Pharmaceuticals in Tarrytown, New York, and colleagues examined two fully human, neutralizing monoclonal antibodies against SARS-CoV-2 spike protein used in a combined cocktail (REGN-COV2) to reduce the risk for the emergence of a treatment-resistant mutant. A total of 275 patients were randomly assigned to receive placebo, 2.4 g REGN-COV2, or 8.0 g REGN-COV2 and were characterized as serum antibody-positive or negative at baseline.

The researchers found that the least-squares mean difference (combined REGN-COV2 dose groups versus placebo) in the time-weighted average change in viral load from day 1 through 7 was −0.56 log10 copies/mL and −0.41 log10 copies/mL among patients who were serum antibody-negative at baseline and in the overall trial population, respectively. In the overall trial population, 6 and 3 percent of patients in the placebo and combined REGN-COV2 groups, respectively, reported at least one medically attended visit; the corresponding percentages were 15 and 6 percent among those who were serum antibody-negative at baseline. Hypersensitivity reactions, infusion-related reactions, and other adverse events did not differ between the REGN-COV2 and placebo groups.

"Our analysis suggests that an antibody cocktail against SARS-CoV2 can also be an effective antiviral therapy, enhancing viral clearance and thus leading to improved outcomes, particularly in patients whose own immune response to the virus is slow to initiate," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Regeneron Pharmaceuticals, which partially funded the study.

Abstract/Full Text

© 2021 HealthDay. All rights reserved.

Posted: December 2020

Read this next

Mortality, Preeclampsia Up for Women With COVID-19 Giving Birth

WEDNESDAY, Jan. 20, 2021 -- Among U.S. women hospitalized for childbirth, the rates of death and certain adverse events are increased among those diagnosed with COVID-19,...

New York City May Run Out of COVID-19 Vaccines

WEDNESDAY, Jan. 20, 2021 -- New York City's COVID-19 vaccination rate has outpaced its supply of vaccine doses, and the city could run out of doses in the next few days, Mayor...

Men More Likely to Test Positive for SARS-CoV-2, Die From COVID-19

WEDNESDAY, Jan. 20, 2021 -- Men are more likely to test positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to have complications of COVID-19, according...

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.